Straits Times Index
3,377.65 +11.98 (+0.36%) S&P 500
4,073.46 -3.14 (-0.08%) Dow
33,937.68 -148.36 (-0.44%) Nasdaq
11,587.12 +2.57 (+0.02%) BTC-USD
23,137.28 -28.90 (-0.12%) CMC Crypto 200
524.13 +281.45 (+115.98%)
ABBV Jun 2024 130.000 put
- Motley Fool
3 Juicy Dividend Stocks in Warren Buffett's Secret Portfolio to Buy in February
Want to know which stocks Warren Buffett owns? Many investors don't realize that there's another group of stocks Buffett owns in addition to the stocks listed in Berkshire's 13-F documents. New England Asset Management (NEAM) is an investment firm that's a wholly owned subsidiary of Berkshire Hathaway.
- Zacks
Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates
Pfizer (PFE) delivered earnings and revenue surprises of 10.68% and 0.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Financial Times
Blockbuster AbbVie drug Humira to face competition in US for first time
For two decades AbbVie has aggressively protected its exclusive right to sell the anti-inflammatory drug Humira in the US, enabling it to ratchet up prices and amass an eye-watering $200bn in total sales since the medicine was launched. Amgen said it would offer its biologic treatment, named Amjevita, to US health insurers and middlemen known as pharmacy benefit managers through two pricing plans. Amgen is offering two pricing plans because in the complex US healthcare system — where the real cost of a drug tends to be decided via opaque deals — some pharmacy benefit managers prefer higher list prices because it allows them to negotiate larger rebates from manufacturers.
